Pramipexole Dihydrochloride Hydrate

盐酸普拉克索

Report date: 2026/05/16 20:00:17
NME

Base Information

Drug NamePramipexole Dihydrochloride Hydrate
Drug Alias Name普拉克索盐酸水合物Pramipexol盐酸普拉克索水合物Sirfrol ER普拉克索 +[25] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D3 receptor agonistsDopamine D4 receptor agonistsDopamine D2 receptor agonists
TargetsDopamine D2 receptorDopamine D4 receptorDopamine D3 receptor
Therapy Area/IndicationsSocial Communication DisorderDysthymic DisorderDepressive Disorder, Major +[17] 
Global Approved IndicationsRestless Legs SyndromeParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryUnited States
Original Approved Date1997/07/01
Country/TerritoryCzechiaUnited StatesUkraine +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim SaC.H. Boehringer Sohn Ag & Co. KgStanford University +[6] 
Inactive CompaniesOregon Health And Science UniversityNational Institute On Drug AbuseVanderbilt University Medical Center +[9] 
Active IndicationsSocial Communication DisorderDepressive Disorder, MajorAnxiety Disorders +[8] 
Inactive IndicationsDysthymic DisorderDepressive DisorderBinge-Eating Disorder +[9] 

Other Information

ATC CodeN04BC05
Related LinksWikipediaDrugBankKEGG